Fast Five Quiz: Do You Know the Risk Factors, Diagnostic Tests, and Treatment for Pancreatic Cancer?

Mary Denshaw-Burke, MD

Disclosures

October 14, 2014

The 2014 NCCN guidelines recommend FOLFIRINOX (leucovorin/5-fluorouracil plus oxaliplatin plus irinotecan) as a first-line treatment for patients with metastatic or locally advanced unresectable disease with good performance status. The NCCN recommended gemcitabine monotherapy for symptomatic patients with metastatic or locally advanced unresectable disease with poor performance status. Additional recommendations for metastatic disease were also added, including the GTX regimen (gemcitabine, docetaxel, and capecitabine) and combination therapy with gemcitabine and nab-paclitaxel.

For more on the treatment and management of pancreatic cancer, read here.

Related Resources

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....